BioLife Solutions Inc (BLFS)

Debt-to-capital ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	4,997	7,823	10,451	15,681	17,561	20,937	23,572	23,692	23,793	24,207	6,188	6,313	6,353	6,122	5,019	916	655	—	—	—
Total stockholders’ equity	US$ in thousands	348,909	325,461	321,442	333,405	337,663	332,017	352,128	358,107	364,188	405,120	409,544	476,075	478,047	489,259	452,281	208,777	204,429	186,851	105,843	67,709
Debt-to-capital ratio		0.01	0.02	0.03	0.04	0.05	0.06	0.06	0.06	0.06	0.06	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $4,997K ÷ ($4,997K + $348,909K)
= 0.01

The debt-to-capital ratio of BioLife Solutions Inc has shown a consistent trend of remaining at a very low level, hovering around 0.00 to 0.01 from March 2020 to June 2022. However, starting from September 2022, there has been a noticeable increase in the ratio, reaching 0.06 by September 2023. The ratio slightly decreased to 0.05 by December 2023 and further declined to 0.04 by March 2024. Subsequently, the ratio decreased to 0.03 by June 2024 and further dropped to 0.02 by September 2024. Finally, as of December 31, 2024, the debt-to-capital ratio stood at 0.01.

This indicates that in recent periods, the company has started to rely more on debt as a source of capital compared to its equity. It's important for stakeholders to monitor this ratio closely as a higher debt-to-capital ratio may indicate increased financial risk and decreased solvency.